232 related articles for article (PubMed ID: 29636136)
1. Enhanced cellular uptake of LHRH-conjugated PEG-coated magnetite nanoparticles for specific targeting of triple negative breast cancer cells.
Hu J; Obayemi JD; Malatesta K; KoĊĦmrlj A; Soboyejo WO
Mater Sci Eng C Mater Biol Appl; 2018 Jul; 88():32-45. PubMed ID: 29636136
[TBL] [Abstract][Full Text] [Related]
2. Investigation of adhesive interactions in the specific targeting of Triptorelin-conjugated PEG-coated magnetite nanoparticles to breast cancer cells.
Hu J; Youssefian S; Obayemi J; Malatesta K; Rahbar N; Soboyejo W
Acta Biomater; 2018 Apr; 71():363-378. PubMed ID: 29458110
[TBL] [Abstract][Full Text] [Related]
3. Adhesion of ligand-conjugated biosynthesized magnetite nanoparticles to triple negative breast cancer cells.
Obayemi JD; Hu J; Uzonwanne VO; Odusanya OS; Malatesta K; Anuku N; Soboyejo WO
J Mech Behav Biomed Mater; 2017 Apr; 68():276-286. PubMed ID: 28226310
[TBL] [Abstract][Full Text] [Related]
4. LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer.
Obayemi JD; Salifu AA; Eluu SC; Uzonwanne VO; Jusu SM; Nwazojie CC; Onyekanne CE; Ojelabi O; Payne L; Moore CM; King JA; Soboyejo WO
Sci Rep; 2020 May; 10(1):8212. PubMed ID: 32427904
[TBL] [Abstract][Full Text] [Related]
5. Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer.
Jusu SM; Obayemi JD; Salifu AA; Nwazojie CC; Uzonwanne V; Odusanya OS; Soboyejo WO
Sci Rep; 2020 Aug; 10(1):14188. PubMed ID: 32843673
[TBL] [Abstract][Full Text] [Related]
6. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
7. Adhesion of LHRH/EphA2 to human Triple Negative Breast Cancer tissues.
Ezenwafor TC; Uzonwanne VO; Madukwe JUA; Amin SM; Anye VC; Obayemi JD; Odusanya OS; Soboyejo WO
J Mech Behav Biomed Mater; 2022 Dec; 136():105461. PubMed ID: 36195050
[TBL] [Abstract][Full Text] [Related]
8. Triptorelin-functionalized PEG-coated biosynthesized gold nanoparticles: Effects of receptor-ligand interactions on adhesion to triple negative breast cancer cells.
Uzonwanne VO; Navabi A; Obayemi JD; Hu J; Salifu AA; Ghahremani S; Ndahiro N; Rahbar N; Soboyejo W
Biomater Adv; 2022 May; 136():212801. PubMed ID: 35929297
[TBL] [Abstract][Full Text] [Related]
9. LHRH-Targeted Redox-Responsive Crosslinked Micelles Impart Selective Drug Delivery and Effective Chemotherapy in Triple-Negative Breast Cancer.
Xiao K; Liu Q; Suby N; Xiao W; Agrawal R; Vu M; Zhang H; Luo Y; Li Y; Lam KS
Adv Healthc Mater; 2021 Feb; 10(3):e2001196. PubMed ID: 33200571
[TBL] [Abstract][Full Text] [Related]
10. Biosynthesis and the conjugation of magnetite nanoparticles with luteinizing hormone releasing hormone (LHRH).
Obayemi JD; Dozie-Nwachukwu S; Danyuo Y; Odusanya OS; Anuku N; Malatesta K; Soboyejo WO
Mater Sci Eng C Mater Biol Appl; 2015 Jan; 46():482-96. PubMed ID: 25492013
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the adhesion of biosynthesized gold and conjugated gold/prodigiosin nanoparticles to triple negative breast cancer cells.
Dozie-Nwachukwu SO; Obayemi JD; Danyuo Y; Anuku N; Odusanya OS; Malatesta K; Soboyejo WO
J Mater Sci Mater Med; 2017 Aug; 28(9):143. PubMed ID: 28819929
[TBL] [Abstract][Full Text] [Related]
12. Design and construction of multifunctional hyperbranched polymers coated magnetite nanoparticles for both targeting magnetic resonance imaging and cancer therapy.
Mashhadi Malekzadeh A; Ramazani A; Tabatabaei Rezaei SJ; Niknejad H
J Colloid Interface Sci; 2017 Mar; 490():64-73. PubMed ID: 27870961
[TBL] [Abstract][Full Text] [Related]
13. In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer.
Eluu SC; Obayemi JD; Salifu AA; Yiporo D; Oko AO; Aina T; Oparah JC; Ezeala CC; Etinosa PO; Ugwu CM; Esimone CO; Soboyejo WO
Sci Rep; 2024 Jan; 14(1):31. PubMed ID: 38167999
[TBL] [Abstract][Full Text] [Related]
14. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
15. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
[TBL] [Abstract][Full Text] [Related]
16. Folic acid-conjugated polyethylene glycol-coated magnetic nanoparticles for doxorubicin delivery in cancer chemotherapy: Preparation, characterization and cytotoxicity on HeLa cell line.
Erdem M; Yalcin S; Gunduz U
Hum Exp Toxicol; 2017 Aug; 36(8):833-845. PubMed ID: 27758842
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis.
Li M; Tang Z; Zhang Y; Lv S; Li Q; Chen X
Acta Biomater; 2015 May; 18():132-43. PubMed ID: 25735801
[TBL] [Abstract][Full Text] [Related]
18. Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide.
Taheri A; Dinarvand R; Atyabi F; Ahadi F; Nouri FS; Ghahremani MH; Ostad SN; Borougeni AT; Mansoori P
Int J Mol Sci; 2011; 12(7):4591-608. PubMed ID: 21845098
[TBL] [Abstract][Full Text] [Related]
19. A comparison inhibitory effects of cisplatin and MNPs-PEG-cisplatin on the adhesion capacity of bone metastatic breast cancer.
Mokhtari MJ; Koohpeima F; Mohammadi H
Chem Biol Drug Des; 2017 Oct; 90(4):618-628. PubMed ID: 28338288
[TBL] [Abstract][Full Text] [Related]
20. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy.
Su YC; Burnouf PA; Chuang KH; Chen BM; Cheng TL; Roffler SR
Nat Commun; 2017 Jun; 8():15507. PubMed ID: 28593948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
